MacuLogix
Advanced dark adaptometers for early AMD detection, enhancing patient outcomes with AI-driven precision and clinical reliability.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
$38.7m | Series D | ||
| Total Funding | 000k | ||
Related Content
MacuLogix operates in the healthcare technology market, specializing in devices that aid in the early detection of age-related macular degeneration (AMD). The company's flagship product, the AdaptDx Pro, is a high-tech dark adaptometer that helps eye care professionals identify AMD in its early stages. The device is powered by artificial intelligence, featuring an on-board technician named Theia, who guides patients through the testing process to ensure consistent and reliable results. MacuLogix serves eye care professionals and practices, providing them with tools to improve patient outcomes through early diagnosis and monitoring of AMD. The business model revolves around selling these advanced diagnostic devices and offering training and support through the AMD Academy, a community platform for continuous learning and professional development. Revenue is generated through the sale of the AdaptDx Pro devices and associated training services.
Keywords: AMD detection, dark adaptometer, eye care, AI-driven, early diagnosis, patient outcomes, clinical reliability, healthcare technology, professional training, precision eye tracking.